SSStephanie Shabanowitz

Stephanie Shabanowitz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stephanie Shabanowitz has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Impact of Glucagon‐Like Peptide‐1 Receptor Agonists on Proteinuria in Kidney Transplant Recipients

    by Stephanie Shabanowitz, Ryan Clark, Rachel Bassett Allen, Mary Chandran, Anita Yang

    Introduction: Proteinuria is a marker of kidney dysfunction and increased cardiovascular mortality. Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have shown significant cardiorenal benefits in chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM). However, the impact of GLP‐1 RAs on cardiorenal outcomes in kidney transplant recipients (KTRs) remains unclear. This study aims to assess the effect of GLP‐1 RA therapy on proteinuria and metabolic parameters in KTRs, with and without T2DM, 12 months following GLP‐1 RA initiation. Methods: A single‐center, retrospective study was conducted to evaluate the safety and efficacy of GLP‐1 RAs in adult KTRs from June 1, 2022 to December 31, 2023. Primary outcomes were changes in urine protein‐creatinine ratio (UPCR) and urine albumin‐to‐creatinine ratio (UACR) at 1, 3, 6, and 12 months after initiation of GLP‐1 RAs. Secondary outcomes assessed changes in estimated glomerular filtration (eGFR), body mass index (BMI), and hemoglobin A1c (A1C). Safety outcomes included cardiovascular hospitalizations, acute kidney injury, pancreatitis, and biopsy‐proven rejection within 12 months. Results: Forty KTRs received GLP‐1 RA therapy with a mean time to initiation of 4.3 months post‐transplant, and the majority of patients had T2DM (87.5%). Baseline UPCR and UACR were 0.86 and 669 mg/g, respectively. UPCR at 1, 3, and 6 months post‐initiation was 0.38 g/g, 0.37 g/g, and 0.30 g/g, respectively. UACR at 1, 3, and 6 months post‐initiation was 313 mg/g, 285 mg/g, and 234 mg/g, respectively. A 55% decrease from baseline in UPCR and UACR was observed at 1 month ( p = 0.070) and a 50% decrease from baseline was observed at 12 months ( p = 0.058), achieving UPCR of 0.43 g/g and UACR of 320 mg/g. A1C, eGFR, and BMI remained stable. Minimal safety events occurred. Conclusion: GLP‐1 RAs demonstrated clinically significant improvements in proteinuria as early as 1 month post‐initiation in KTRs. Proteinuria significantly improved from severely increased to moderately increased at 6 months following GLP‐1 RAs, with good tolerability. GLP‐1 RAs may offer renal benefits in KTRs with T2DM without compromising allograft function. Future studies should include closer monitoring of KTRs on immunosuppression with high gastrointestinal adverse effect profiles, and larger studies are needed to assess the long‐term impact of GLP‐1 RAs in KTRs irrespective of T2DM.

  • Impact of Sodium‐Glucose Cotransporter‐2 Inhibitors on Proteinuria in Kidney Transplant Recipients

    by Emili Anderson, Stephanie Shabanowitz, Kinley Jessup, Rachel Bassett Allen, Mary Chandran, Anita Yang

    Introduction: Proteinuria is a marker of kidney dysfunction and increased cardiovascular mortality. Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated cardiorenal protection in chronic kidney disease, regardless of type 2 diabetes mellitus (T2DM) status. However, data evaluating SGLT2i impact on cardiorenal outcomes in kidney transplant recipients (KTRs) are limited. Methods: This single‐center, retrospective cohort study evaluated the safety and efficacy of SGLT2i therapy in adult KTRs transplanted between January 1, 2020 and December 31, 2023. Primary outcomes were changes in urine protein‐to‐creatinine ratio (UPCR) and urine albumin‐to‐creatinine ratio (UACR) at 1‐, 3‐, 6‐, and 12‐months post‐initiation. Secondary outcomes included changes in estimated glomerular filtration rate (eGFR), BMI, and hemoglobin A1c (HbA1c). Safety outcomes were cardiovascular hospitalization, acute kidney injury, urinary tract infection, and biopsy‐proven rejection within 12 months. Results: SGLT2i therapy was initiated in 77 KTRs, 524 days post‐transplant, predominantly in males (74.3%), African Americans (62.8%), and patients with T2DM (80.7%). Baseline UPCR and UACR were 0.387 g/g and 302.2 mg/g, respectively. No significant changes in UPCR, UACR, or eGFR were observed. Renal function was preserved at 12 months, with a transient decline at 1‐month that returned to baseline by 3 months. HbA1c and BMI remained stable. Few safety events occurred. Conclusions: In KTRs with moderate proteinuria, SGLT2i therapy was well tolerated with stable renal function over 12 months. A transient eGFR dip is consistent with patterns seen in non‐transplant populations. Absence of significant metabolic changes may reflect well‐controlled baseline parameters. Further studies are warranted to evaluate SGLT2i benefits in KTRs, especially in patients with higher grade proteinuria or early post‐transplant initiation.